Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

ADAMA Ltd.: ADAMA Provides Financial Performance Estimation for the Full Year of 2024

Finanznachrichten News

TEL AVIV, ISRAEL and BEIJING, Jan. 22, 2025 /PRNewswire/ -- ADAMA Ltd. (the "Company") (SZSE: 000553), today provided an estimate regarding its financial performance for the full year of 2024. In early 2024, ADAMA launched 'Fight Forward', a strategic transformation plan aimed at gradually delivering improved profit and cash-targets over a three-year period. Improvements in certain key metrics, including free cash flow and adjusted financial results in 2024, reflect the plan's initial impact.

Sales

For the full year of 2024, ADAMA is expecting to report a decline in revenues of approximately 7% to 16% in USD to $3,934 million to $4,348 million (28 billion to 31 billion RMB), compared to the full year of 2023. The lower revenues mainly reflect lower prices in 2024, due to just-in-time purchasing patterns of the channel in light of price volatility and a higher interest rate ?environment, despite improved channel inventory levels.

Volumes in Q4 2024 were up compared with Q4 2023 despite the Company's shift away from selected low-profit products, marking the second consecutive quarter of volume growth.

Adjusted EBITDA and Net Loss

For the full year of 2024, the Company is expecting to report an increase in adjusted EBITDA and in its margin, in comparison to the full year of 2023. Despite the decrease in revenues, adjusted EBITDA and its margin improved due to an increase in the gross margin, mainly reflecting the positive impact of lower costs of new inventory sold, an improved sales mix towards higher-margin products, and continued control of operating expenses, all following implementation of the Fight Forward plan.

The Company expects to report an adjusted net loss in the range of USD 151 million to 261 million for the full year of 2024, compared to a loss of USD 236 million for the full year of 2023. The loss is attributable to higher adjusted operating profit and a decrease in financial expenses, in light of lower interest paid on loans, lower put option revaluation, as well as the net impact of a lower Israeli CPI on the ILS-denominated CPI-linked bonds, despite higher tax expenses.

Adjusted Net Loss


Estimated
Full Year
202 4


Full Year 202 3


Net loss attributable to shareholders (USD millions)


(261)-(151)


(236)



Earnings per share (USD)


(0.112)-(0.0648)


(0.1013)



Net loss attributable to shareholders (RMB millions)


(1,860)-(1,073)


(1,691)



Earnings per share (RMB)


(0.7982)-(0.4604)


(0.7260)



Adjusted Net loss excludes the impact of transitory, non-operational or non-cash items, mainly including:

i. Non-cash amortization charges in respect of transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition;

ii. Non-cash amortization net charges related to intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired;

iii. Restructuring costs incurred as part of the implementation of the Fight Forward transformation plan;

iv. Fixed asset impairment related to improvement of operational efficiency, as part of the Fight Forward plan;

v. Provisions such as legal claims, registration impairment and ?update of registration depreciation;

vi. Soil and water cleanup and remediation;

vii. Financial expenses including non-cash adjustments related to revaluation of put options attributed to minority stakes in subsidiaries, and expenses deriving from tax claims surcharges and inflation.

Reported EBITDA and Net Loss

The Company expects lower reported EBITDA and deepened reported net loss (which include the impact of the above adjusted items) for the full year of 2024 compared to 2023. This expectation is mainly due to lower reported operating profit and a higher tax burden, despite a decrease in financial expenses as explained above.

Reported Net Loss


Estimated
Full Year
202 4


Full Year 202 3


Net loss attributable to shareholders (USD millions)


(470)-(360)


(225)


Earnings per share (USD)


(0.2017)-(0.1545)


(0.0964)


Net loss attributable to shareholders (RMB millions)


(3,351)-(2,564)


(1,606)


Earnings per share (RMB)


(1.4384)-(1.1006)


(0.6893)


The estimated results of the Company are a preliminary estimation of the Company and have not been audited or reviewed by certified accountants. However, the Company and the external auditor have preliminarily communicated regarding relevant matters of the performance estimation and have no material disagreement. These estimations may change as a result of the further processing and analysis of the financial data that the Company will perform for the preparation of its financial statements, which are expected to be released after trading hours on March 13, 2025.

Investors are reminded to exercise caution when making investment decisions.

About ADAMA

ADAMA Ltd. is a global leader in crop protection, providing practical solutions to farmers across the world to combat weeds, insects and disease. Our culture empowers ADAMA's people to actively listen to farmers and ideate from the field. ADAMA's diverse portfolio of existing active ingredients, coupled with its leading formulation capabilities and proprietary formulation technology platforms, uniquely position the company to develop high-quality, innovative and sustainable products, to address the many challenges farmers and customers face today. ADAMA serves customers in dozens of countries globally, with direct presence in all top 20 markets. For more information, visit us at www.ADAMA.com and follow us on X at @ADAMAAgri.

Contact

Joshua Phillipson


Zhujun Wang


Global Investor Relations


China Investor Relations


Email: [email protected]


Email: [email protected]


Logo: https://mma.prnewswire.com/media/799829/Adama_Agricultural_Solutions_Logo.jpg

SOURCE ADAMA Ltd.

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.